LBRX
LB Pharmaceuticals Inc19.82
-0.04-0.2%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
501.43MP/E (TTM)
-Basic EPS (TTM)
-0.74Dividend Yield
0%Recent Filings
10-K
FY2025 results
LB Pharmaceuticals posted FY2025 ended December 31, 2025 results reflecting its clinical-stage status with no revenue disclosed in the 10-K, focusing instead on pipeline momentum. Phase 2 NOVA-1 trial in acute schizophrenia hit primary endpoint with statistically significant PANSS reductions across 50mg, 75mg, and 100mg doses versus placebo (14.3, 14.0, 16.1-point drops), showing early Day 8 benefits and effect sizes up to 0.83. Q4 wrapped positive topline read in January 2025; Phase 3 NOVA-2 launched March 2026 eyeing H2 2027 data. Bipolar depression Phase 2 started January 2026. Cash position not detailed. Clinical delays could stall quarterly progress.
8-K
Q4 loss widens; cash runway to 2029
LB Pharmaceuticals reported Q4 2025 net loss of $11.5 million, up from $5.1 million prior year, with R&D expenses at $8.5 million amid Phase 3 schizophrenia and Phase 2 bipolar depression trial startups. Cash hit $295.2 million at year-end, bolstered by $100 million private placement for runway into Q2 2029. Pipeline expands to MDD Phase 2 in early 2027.
8-K
Director Prensky to retire
LB Pharmaceuticals director Zachary Prensky notified the board on March 13, 2026, of his retirement, opting not to stand for reelection at the 2026 annual meeting. His term ends then, but he'll stay on until the meeting and provide post-separation consulting via an amended agreement effective June 3, 2026. Unvested stock options continue vesting. No disagreements with company practices.
8-K
Board and COO appointments
LB Pharmaceuticals appointed Robert Lenz, M.D., Ph.D., a neuroscience R&D veteran from Neumora and Amgen, to its board on March 6, 2026, adding him to the Nominating and Governance Committee. Separately, on March 4, it promoted Gad Soffer to Chief Operating and Business Officer with base salary raised to $505,000 and 40% target bonus. These moves bolster expertise as LB-102 advances in late-stage trials. No related transactions disclosed.
8-K
LB Pharma raises $100M for MDD trial
LB Pharmaceuticals inked a $100M private placement on February 4, 2026, issuing 3.3M shares at $21.17 and pre-funded warrants for 1.4M more, closing February 6. Funds fuel a Phase 2 trial of LB-102 for MDD adjunctive therapy starting early 2027, topline data H1 2029. Cash extends runway. Trial risks loom large.
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CYBN
Cybin Inc.
6.66+0.00
DRUG
Bright Minds Biosciences Inc.
93.99+8.32
FBRX
Forte Biosciences, Inc.
23.27+1.31
LENZ
LENZ Therapeutics, Inc.
16.70-0.38
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01